Antibody-drug conjugate targeting glypican-1 inhibits tumor growth and tumor angiogenesis for glypican-1 positive cholangiocarcinoma.

被引：0
|
作者：
Yokota, Keiichiro [1 ]
Serada, Satoshi [1 ]
Tsujii, Shigehiro [1 ]
Murakami, Ichiro [1 ]
Hanazaki, Kazuhiro [1 ]
Naka, Tetsuji [1 ]
机构：
[1] Kochi Med Sch, Nankoku, Kochi, Japan
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1315
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor
    Berman, B
    Ostrovsky, O
    Shlissel, M
    Lang, T
    Regan, D
    Vlodavsky, I
    Ishai-Michaeli, R
    Ron, D
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (51) : 36132 - 36138
  • [32] Growth and sex effects on the expression of syndecan-4 and glypican-1 in turkey myogenic satellite cell populations
    Song, Yan
    McFarland, Douglas C.
    Velleman, Sandra G.
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2013, 378 (1-2) : 65 - 72
  • [33] Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
    Yeh, Mei-Chun
    Tse, Brian W. C.
    Fletcher, Nicholas L.
    Houston, Zachary H.
    Lund, Maria
    Volpert, Marianna
    Stewart, Chelsea
    Sokolowski, Kamil A.
    Jeet, Varinder
    Thurecht, Kristofer J.
    Campbell, Douglas H.
    Walsh, Bradley J.
    Nelson, Colleen C.
    Russell, Pamela J.
    EJNMMI RESEARCH, 2020, 10 (01)
  • [34] A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis
    C A Whipple
    A L Young
    M Korc
    Oncogene, 2012, 31 : 2535 - 2544
  • [35] Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells
    Ding, K
    Lopez-Burks, M
    Sánchez-Duran, JA
    Korc, M
    Lander, AD
    JOURNAL OF CELL BIOLOGY, 2005, 171 (04): : 729 - 738
  • [36] Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
    Mei-Chun Yeh
    Brian W. C. Tse
    Nicholas L. Fletcher
    Zachary H. Houston
    Maria Lund
    Marianna Volpert
    Chelsea Stewart
    Kamil A. Sokolowski
    Varinder Jeet
    Kristofer J. Thurecht
    Douglas H. Campbell
    Bradley J. Walsh
    Colleen C. Nelson
    Pamela J. Russell
    EJNMMI Research, 10
  • [37] A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis
    Whipple, C. A.
    Young, A. L.
    Korc, M.
    ONCOGENE, 2012, 31 (20) : 2535 - 2544
  • [38] A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
    Maria E. Lund
    Christopher B. Howard
    Kristofer J. Thurecht
    Douglas H. Campbell
    Stephen M. Mahler
    Bradley J. Walsh
    BMC Cancer, 20
  • [39] Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma
    Harada, Emi
    Serada, Satoshi
    Fujimoto, Minoru
    Takahashi, Yusuke
    Takahashi, Tsuyoshi
    Hara, Hisashi
    Nakatsuka, Rie
    Sugase, Takahito
    Nishigaki, Takahiko
    Saito, Yurina
    Hiramatsu, Kosuke
    Nojima, Satoshi
    Mitsuo, Risa
    Ohkawara, Tomoharu
    Morii, Eiichi
    Mori, Masaki
    Doki, Yuichiro
    Kaneda, Yasufumi
    Naka, Tetsuji
    ONCOTARGET, 2017, 8 (15) : 24741 - 24752
  • [40] The role of glypican-1 glycosaminoglycan chains in myogenic satellite cell proliferation, differentiation, and fibroblast growth factor 2 responsiveness
    Zhang, X.
    Liu, C.
    Nestor, K. E.
    McFarland, D. C.
    Velleman, S. G.
    JOURNAL OF DAIRY SCIENCE, 2007, 90 : 389 - 389
12345